Selepressin
An investigational selective vasopressin V1a-receptor agonist studied in septic shock.
- Evidence grade
- CEarly Human Research
Early Human Research
- Regulatory status
- Not FDA Approved
Not FDA-approved; the phase 2b/3 SEPSIS-ACT trial was terminated for futility.
- Human data
- Yes
Registered clinical trials exist
- Last reviewed
- October 27, 2026
Overview
An investigational selective vasopressin V1a-receptor agonist studied in septic shock.
Not FDA-approved; the phase 2b/3 SEPSIS-ACT trial was terminated for futility.
Receptor selectivity did not establish superior patient outcomes; unsuccessful development is not an approved shock treatment.
Why It's Being Studied
- Septic shock
- V1a receptor signalling
Mechanism of Action
V1a-receptor activation is intended to support vascular tone with a different selectivity profile from vasopressin.
V1a-receptor activation is intended to support vascular tone with a different selectivity profile from vasopressin. Receptor selectivity did not establish superior patient outcomes; unsuccessful development is not an approved shock treatment.
From molecular target to clinical evidence
Tap each stage to see what happens.
Background: Clinical Peptide Medicines
Clinical peptide medicines include endocrine treatments, antimicrobial drugs, receptor blockers and targeted diagnostic or cancer agents. They do not share one mechanism or one set of indications.
An approval belongs to a specific medicine and indication. A diagnostic tracer, an antibiotic and a hormone are not interchangeable wellness products; read each profile's own mechanism and prescribing source.
Research Areas & Routes Studied
- Septic shock
- V1a receptor signalling
- Intravenous clinical research
Evidence Summary
SEPSIS-ACT was terminated for futility and did not improve ventilator- and vasopressor-free days.
Higher tiers carry more weight. Filled tiers have evidence for Selepressin; tap to read it.
- SEPSIS-ACT was terminated for futility and did not improve ventilator- and vasopressor-free days.
1 cited sources.
- Regulatory document1
Human clinical evidence
- SEPSIS-ACT was terminated for futility and did not improve ventilator- and vasopressor-free days.
Reported Adverse Events in Research
- Vasoconstriction-related ischemic concerns and critical-care adverse events matter.
Limitations of Current Evidence
- Receptor selectivity did not establish superior patient outcomes; unsuccessful development is not an approved shock treatment.
- Findings apply to the product, route and population studied; they do not establish benefits or safety for unrelated wellness uses or research-vial products.
How to Read This Research
- Is this a single molecule or a family of medicines?
- Is the use diagnostic, therapeutic or investigational?
- Does the quoted outcome match the exact product, formulation and population?
- Use the compound-specific mechanism above; this diagram describes drug development, not a shared biological pathway.
- Historical approval, present availability and off-label use are distinct questions.
- For radiopharmaceuticals and hospital medicines, specialist handling is part of the treatment context.
- Indication
- The condition and population for which a medicine is approved.
- Antagonist
- A compound that blocks activity at a receptor.
- Radiopharmaceutical
- A medicine containing a radioactive isotope for imaging or treatment.
Compare With Other Compounds
| Selepressin | Trofinetide | |
|---|---|---|
| Evidence grade | C — Early Human Research | B — Moderate Human Evidence |
| Regulatory status | Not FDA Approved | FDA Approved for Specific Indication |
| Human data | Yes | Yes |
| Clinical trials | Registered trials exist | Registered trials exist |
| Research routes | Intravenous clinical research | Oral approved medicine |
| Cited sources | 1 | 2 |
Frequently Asked Questions
Research References
- Regulatory document
Selepressin — regulatory document